Unlocking Cell Therapies
For Cancer

AI-Powered Discovery Of T-Cell-Receptor-Based Cancer Immunotherapies

Data

In-house generation of massive TCR-target interaction datasets using cutting-edge
high-throughput screening techniques

Model

In silico predictions of TCR-target interactions through deep learning models trained on our proprietary datasets

Discover

Discovery of novel tumour targets shared across patients and safe and effective target-specific TCRs

Our team

Federico Paoletti

CEO and CO-FOUNDER

PhD in Molecular and Computational Oncology (University of Oxford, UK) and deep expertise in mathematical modelling and molecular biophysics. Previously worked at the World Health Organisation assessing cancer prevention strategies.

Andrea Mambrini

CTO and CO-FOUNDER

PhD in Bio-Inspired Computation (University of Birmingham, UK) and several years of hands-on experience building cutting-edge AI software tools across the space, media, automotive and marketing industries.

Ricardo Fernandes

Scientific Advisor

Principal Investigator  at University of Oxford. World expert in  wet-lab methods for high-throughput screening of TCR-target pairs. Published in high-profile journals such as Nature Immunology, Cell and PNAS.

Alasdair Thong

Commercial Advisor

Founding partner at Selvedge Venture. Ex-director of deep-tech venture investments at Leaps for Bayer. Extensive experience negotiating and managing AI-driven co-development partnerships in the biopharmaceutical industry.

Featured

Email:

info@exogene.co.uk

Reg. Number:

12293407

Address:

Exogene Limited, Internatonal House, 24 Holborn Viaduct, EC1A 2BN, London, United Kingdom